E. Ohman J or Asset Management AB Raises Stake in Boston Scientific Corporation $BSX

E. Ohman J or Asset Management AB increased its position in Boston Scientific Corporation (NYSE:BSX) by 42.0% during the 4th quarter, Holdings Channel reports. The firm owned 564,471 shares of the medical equipment provider’s stock after acquiring an additional 167,052 shares during the quarter. Boston Scientific comprises approximately 1.3% of E. Ohman J or Asset Management AB’s investment portfolio, making the stock its 14th largest holding. E. Ohman J or Asset Management AB’s holdings in Boston Scientific were worth $53,822,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Gerber Kawasaki Wealth & Investment Management boosted its position in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 99 shares in the last quarter. Crown Wealth Group LLC grew its stake in shares of Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the last quarter. Claret Asset Management Corp increased its stake in Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC increased its position in shares of Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares during the period. Finally, Scotia Capital Inc. increased its holdings in shares of Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after purchasing an additional 104 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. National Bank Financial set a $115.00 price target on Boston Scientific in a research report on Monday, February 2nd. Stifel Nicolaus lowered their target price on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday. Citigroup reduced their price target on Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Finally, Morgan Stanley dropped their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $106.27.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham & Company reiterated a “Buy” rating on BSX, reinforcing institutional support for the shares amid the post-earnings pullback; this helps underpin demand from investors looking for growth exposure in medical devices. Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Several market write-ups argue the pullback could be a buying opportunity given solid recent fundamentals (beat on adjusted EPS, strong free cash flow, growth in EP and Watchman) and potential catalysts such as Champion-AF trial results and the planned Penumbra acquisition — but these are contingent on upcoming clinical and integration outcomes. Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for a securities class action covering purchases between July 23, 2025 and Feb 3, 2026; they remind investors of a May 4, 2026 lead-plaintiff deadline — this increases legal overhang and potential litigation costs/settlement risk. ROSEN – Class Action Notice Robbins LLP – Class Action Alert Faruqi & Faruqi – Class Action Notice
• Negative Sentiment: MassDevice reports alleged long-running pacemaker battery problems — product reliability and potential recalls or regulatory scrutiny could materially affect device sales and margins if issues are confirmed and widespread. Boston Scientific has reportedly had pacemaker battery problems for years
• Negative Sentiment: Stifel cut its price target on BSX to $90, signaling some analyst caution and reduced near-term upside expectations even where ratings remain constructive — this can weigh on sentiment and caps potential rebound momentum. Stifel Nicolaus Cuts Boston Scientific Price Target to $90

Boston Scientific Stock Up 0.1%

Shares of NYSE BSX opened at $69.54 on Tuesday. The business’s 50 day moving average is $79.22 and its two-hundred day moving average is $91.68. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm has a market cap of $103.34 billion, a price-to-earnings ratio of 35.84, a PEG ratio of 0.97 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.